ArticleArXiv2025
Training Together, Diagnosing Better: Federated Learning for Collagen VI-Related Dystrophies.
Article in ArXiv, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The application of Machine Learning (ML) to the diagnosis of rare diseases, such as collagen VI-related dystrophies (COL6-RD), is fundamentally limited by the scarcity and fragmentation of available data. Attempts to expand sampling across hospitals, institutions, or countries with differing regulations face severe privacy, regulatory, and logistical obstacles that are often difficult to overcome. The Federated Learning (FL) provides a promising solution by enabling collaborative model training across decentralized datasets while keeping patient data local and private. Here, we report a novel global FL initiative using the Sherpa.ai FL platform, which leverages FL across distributed datasets in two international organizations for the diagnosis of COL6-RD, using collagen VI immunofluorescence microscopy images from patient-derived fibroblast cultures. Our solution resulted in an ML model capable of classifying collagen VI patient images into the three primary pathogenic mechanism groups associated with COL6-RD: exon skipping, glycine substitution, and pseudoexon insertion. This new approach achieved an F1-score of 0.82, outperforming single-organization models (0.57-0.75). These results demonstrate that FL substantially improves diagnostic utility and generalizability compared to isolated institutional models (see Figure 1). Beyond enabling more accurate diagnosis, we anticipate that this approach will support the interpretation of variants of uncertain significance and guide the prioritization of sequencing strategies to identify novel pathogenic variants.
Identifiers
42147733PMC13175213What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.